Peer-influenced content. Sources you trust. No registration required. This is HCN.

Articles related to CAR-T THERAPY

The New England Journal of Medicine

GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma

Oncology, Medical April 10th 2023

The New England Journal of Medicine

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

Hematology March 13th 2023


Selecting CAR T-cell Therapy for Patients with Late Relapsed Multiple Myeloma

Hematology March 6th 2023

Roswell Park

Roswell Park Researchers Present New Approach to Understanding Challenging CAR T-Cell Toxicities

Oncology, Medical February 27th 2023

OBR Oncology

Mantle Cell Lymphoma: Optimizing Current Therapies

Oncology, Medical January 3rd 2023

Hematology, ASH Education Program

Transformed Lymphoma: What Should I Do Now?

Hematology December 19th 2022

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form